SAN DIEGO, Nov. 24, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT. Dr. Helen Torley, president and CEO, will provide a corporate overview.
On Tuesday, December 8, Halozyme will also present at the 26th Annual Oppenheimer Healthcare Conference in New York at 1:00 p.m. ET/10:00 a.m. PT. Jim Mazzola, vice president of corporate communication and investor relations, will provide a corporate overview.
Both presentations will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following each event. To access the live webcast, please log on to Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.
About Halozyme Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen and AbbVie for its drug delivery platform, ENHANZE™, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.
Contacts: Jim Mazzola 858-704-8122 firstname.lastname@example.org
SOURCE Halozyme Therapeutics, Inc.